Experts discuss wet AMD treatment limits and need for longer lasting therapies

In a recent episode of the Denatured podcast, Professor Philip Jacob Rosenfeld of the University of Miami and Wesley Jackson, chief science officer at Valitor, joined host Jennifer C. Smith-Parker to talk about wet age-related macular degeneration.

The conversation highlighted how current anti-VEGF injections, while standard, often require frequent dosing and may not provide lasting vision improvement for many patients.

Both guests emphasized the industry’s drive to develop truly durable therapies that could reduce treatment burden and meaningfully improve quality of life for those living with wet AMD.